MAIA

MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer. The company's proprietary platform leverages telomere biology to selectively target and destroy cancer cells. MAIA's lead program, ateganosine (THIO), is a first-in-class small molecule telomere-targeting agent currently in Phase 3 clinical development (THIO-104) and Phase 2 clinical development (THIO-101) for the treatment of advanced non-small cell lung cancer (NSCLC). Additionally, MAIA is advancing a pipeline of second-generation telomere-targeting agents, including MAIA-2021-20 and MAIA-2022-12, designed to enhance antitumor activity and overcome drug resistance across multiple solid tumor types.